Skip to content

Annexon ANNX Free cash flow yield

Free cash flow yield at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
5%+0.6pp
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
-7%+0.3pp
Omeros logo
OmerosOMER
-12.7%-4.6pp
Vor Biopharma logo
Vor BiopharmaVOR
-17.3%-7.9pp
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-20.5%-5.1pp
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-9.9%-4.8pp

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+223%
Enterprise value$718.59M+261%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Calculated from Annexon’s reported figures.

Based on trailing twelve months.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's free cash flow yield?
Annexon (ANNX) reported free cash flow yield of -22.2% in Q1 2026.
What is the long-term trend for Annexon's free cash flow yield?
Over 3 years (2021 to 2025), Annexon's free cash flow yield has grown at a 0.7% compound annual growth rate (CAGR), from -24.4% to -24.9%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.